BIO-key International (NASDAQ:BKYI) Posts Earnings Results, Misses Estimates By $0.12 EPS

BIO-key International (NASDAQ:BKYI) posted its quarterly earnings results on Tuesday. The technology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.12), FiscalAI reports. BIO-key International had a negative return on equity of 73.33% and a negative net margin of 70.23%.The company had revenue of $1.24 million during the quarter, compared to analysts’ expectations of $2.20 million.

Here are the key takeaways from BIO-key International’s conference call:

• Company expects Q1 2026 revenue of approximately $2.2 million (up ~37% YoY) and a “substantial” improvement in Q1 bottom-line performance versus any 2025 quarter.
• 2025 revenues fell 12% to $6.1 million, largely due to timing from a prior two?year $1.5M license recognized in 2024 and a slower-than-expected EMEA transition to BIO-key?branded solutions, while hardware and services grew.
• Product roadmap momentum: launched the FBI FAP 20 certified EcoID III fingerprint scanner and plans a major PortalGuard v7.0 release (multi-tenant, monetization, security testing) expected in Q2.
• Commercial traction and partnerships are strengthening—capabilities in passwordless/biometric auth target regulated verticals (defense, financial services, healthcare) and a new channel relationship with TD SYNNEX is positioned as a force multiplier.
• Financials show improved liquidity and cost control—year-end cash of $2.7M (up >$2M YoY), SG&A down ~11% and operating expenses down 7%—but net loss widened to $4.6M as the company targets breakeven/profitability in 2026.

BIO-key International Stock Performance

BKYI stock opened at $0.53 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.26 and a quick ratio of 1.13. The business has a 50-day moving average price of $0.63 and a 200 day moving average price of $0.70. The company has a market capitalization of $5.70 million, a P/E ratio of -0.75 and a beta of 0.50. BIO-key International has a 1-year low of $0.49 and a 1-year high of $1.97.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BKYI shares. Weiss Ratings restated a “sell (e+)” rating on shares of BIO-key International in a research note on Wednesday, January 21st. Wall Street Zen raised shares of BIO-key International to a “sell” rating in a research note on Saturday, January 3rd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BIO-key International stock. Geode Capital Management LLC grew its holdings in BIO-key International Inc. (NASDAQ:BKYI) by 49.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 48,892 shares of the technology company’s stock after purchasing an additional 16,271 shares during the quarter. Geode Capital Management LLC owned approximately 0.45% of BIO-key International worth $26,000 at the end of the most recent reporting period. 26.51% of the stock is owned by hedge funds and other institutional investors.

About BIO-key International

BIO-key International, Inc is a developer and provider of fingerprint biometric identity and access management solutions, serving enterprise and government customers. The company’s core offerings include a range of fingerprint readers and authentication software designed to verify user identity across physical and digital environments. By leveraging proprietary template-on-card and template-on-device technologies, BIO-key seeks to enhance security and streamline user access without reliance on traditional passwords.

In addition to hardware sensors, BIO-key delivers software platforms that integrate with existing IT infrastructures such as Microsoft Active Directory and major workforce management systems.